Who founded Sionna Therapeutics?

Sionna Therapeutics was founded by Greg, Mark in 2019.

Who are Sionna Therapeutics's investors?

Sionna Therapeutics's investors include Atlas Venture, OrbiMed, RA Capital, Viking Global.

Sionna Therapeutics

NASDAQ: SION

Founded 2019 · 76 employees on LinkedIn · 4 known investors

Find your way into Sionna Therapeutics

Your email: who you already know at Sionna Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sionna Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.

Biotech Healthtech Medical Devices

Founders & leadership

Sionna Therapeutics was founded in 2019 by Greg and Mark.

GregCo-founder & Senior Vice President of Discovery Research

MarkCo-founder & Senior Vice President of Medicinal Chemistry

MikePresident & CEO

CharlotteChief Medical Officer

ElenaChief Financial Officer

CarolineChief Business Officer

JenChief Legal Officer

VanyaChief People Officer

Investors · 4

Atlas Venture✓ confirmed by Sionna TherapeuticsCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · the company's own site · the S-1 prospectus · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

OrbiMed✓ confirmed by Sionna TherapeuticsNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the company's own site · the S-1 prospectus · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

RA Capital✓ confirmed by Sionna TherapeuticsBoston

How we know: RA Capital's portfolio page · the company's own site · the S-1 prospectus · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

Valuation · disclosed

Disclosed events

$765.7Mvaluation at IPOFeb 2025 · $18.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Sionna Therapeutics do?: Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Who founded Sionna Therapeutics?: Sionna Therapeutics was founded by Greg, Mark in 2019.
Who are Sionna Therapeutics's investors?: Sionna Therapeutics's investors include Atlas Venture, OrbiMed, RA Capital, Viking Global.